[go: up one dir, main page]

BR9301420A - Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso - Google Patents

Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso

Info

Publication number
BR9301420A
BR9301420A BR9301420A BR9301420A BR9301420A BR 9301420 A BR9301420 A BR 9301420A BR 9301420 A BR9301420 A BR 9301420A BR 9301420 A BR9301420 A BR 9301420A BR 9301420 A BR9301420 A BR 9301420A
Authority
BR
Brazil
Prior art keywords
vector
compound
preparation
pharmaceutical composition
host cell
Prior art date
Application number
BR9301420A
Other languages
English (en)
Inventor
Werner Lesslauer
Hansruedi Loetscher
Dietrich Stueber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9301420A publication Critical patent/BR9301420A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9301420A 1992-04-02 1993-04-02 Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso BR9301420A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92810249 1992-04-02

Publications (1)

Publication Number Publication Date
BR9301420A true BR9301420A (pt) 1993-10-05

Family

ID=8211902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9301420A BR9301420A (pt) 1992-04-02 1993-04-02 Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso

Country Status (19)

Country Link
US (1) US5486463A (pt)
EP (1) EP0563714A3 (pt)
JP (1) JPH07285997A (pt)
CN (1) CN1037844C (pt)
AU (1) AU659927B2 (pt)
BR (1) BR9301420A (pt)
CA (1) CA2091313A1 (pt)
CZ (1) CZ283533B6 (pt)
FI (1) FI931488A (pt)
HU (1) HUT69790A (pt)
IL (1) IL105170A0 (pt)
MX (1) MX9301700A (pt)
NO (1) NO931141L (pt)
NZ (1) NZ247265A (pt)
PL (1) PL298345A1 (pt)
SK (1) SK376492A3 (pt)
TW (1) TW260707B (pt)
UY (1) UY23561A1 (pt)
ZA (1) ZA932177B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
CN1049663C (zh) * 1994-09-01 2000-02-23 中国科学院上海生物工程研究中心 突变的人肿瘤坏死因子
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
PL377119A1 (pl) * 2001-08-03 2006-01-23 Genentech, Inc. Peptydy TACIs i BR3 i ich zastosowanie
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030199024A1 (en) * 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
MXPA05000940A (es) * 2002-07-25 2005-05-16 Genentech Inc Anticuerpos taci y su uso.
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CN100390200C (zh) * 2003-11-24 2008-05-28 中国医学科学院基础医学研究所 一种用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
CN1752211B (zh) * 2004-09-23 2010-09-15 中国医学科学院基础医学研究所 用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
EP1952150B1 (en) * 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
IL301787A (en) 2020-10-01 2023-05-01 Immunicom Inc Reduced leaching of a ligand

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins

Also Published As

Publication number Publication date
HUT69790A (en) 1995-09-28
IL105170A0 (en) 1993-07-08
NZ247265A (en) 1995-10-26
UY23561A1 (es) 1993-09-20
EP0563714A3 (en) 1993-11-10
EP0563714A2 (en) 1993-10-06
NO931141D0 (no) 1993-03-26
FI931488A0 (fi) 1993-04-01
CN1079225A (zh) 1993-12-08
CA2091313A1 (en) 1993-10-03
AU659927B2 (en) 1995-06-01
CZ283533B6 (cs) 1998-04-15
US5486463A (en) 1996-01-23
CZ376492A3 (en) 1994-01-19
ZA932177B (en) 1993-10-04
HU9300843D0 (en) 1993-06-28
FI931488A (fi) 1993-10-03
NO931141L (no) 1993-10-04
CN1037844C (zh) 1998-03-25
JPH07285997A (ja) 1995-10-31
MX9301700A (es) 1993-10-29
AU3561193A (en) 1993-10-07
PL298345A1 (en) 1993-12-27
TW260707B (pt) 1995-10-21
SK376492A3 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
BR9301420A (pt) Muteina de fator de necrose,sequencia de dna,vetor,celula hospedeira,composto,processo para sua preparacao,composicao farmaceutica e uso
BR9401321A (pt) Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.
BR9200951A (pt) Compostos, processo para sua producao,preparacoes farmaceuticas e uso
BR9301137A (pt) Composto,formulacao farmaceutica,sulfonamida e processo para sua preparacao
ITRM940621A0 (it) "composizione farmaceutica stabilizzata, relativo solvente e procedimento di preparazione"
BR8906988A (pt) Tetrapiptidio,peptidio,composicao farmaceutica,processo para uso de peptidio e reagente para diagnostico
FI954329A (fi) Farmaseuttisina aineina käytettäviä nukleiinihappoja
BR9501770A (pt) Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
BR9801606B1 (pt) composto, processo para sua preparação, substáncia farmacêutica, uso do composto e processo para a produção de uma substáncia farmacêutica.
BR9404809A (pt) Composto, uso, formulação farmacêutica e processo para preparar um composto
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9601093A (pt) Pirido(3,2-E)pirazinoas processo para sua preparação medicamentos processo para sua preparação e utilização
ZA974574B (en) Novel guanidine derivatives process for their preparations and their use as pharmaceuticals.
DK394489A (da) I para-stillingen heterocyclisk substituerede n-phenylamidforbindelser, mellemprodukter ved deres fremstilling, farmaceutiske praeparater indeholdende forbindelserne og anvendelse af forbindelserne til fremstilling af antiarytmiske laegemidler
BR9600147A (pt) Purin-6-onas 2,9-DI-substituidas processo para sua preparação medicamentos e uso
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
BR9503876A (pt) Quinoxalina-2,3-diona-oxa-ou tec-alifaticamente ligada em ponte processo para sua preparação compostos uso dos mesmos e composições farmacêuticas
BR9106744A (pt) Processo para induzir diferenciacao celular,preparacao farmaceutica,composicao e uso de um composto
BR9302359A (pt) Composto,processo para sua preparacao,medicamento e uso
BR9106555A (pt) Proteina,celula hospedeira e processos para a preparacao de uma proteina e de acido nucleico
BR9600779A (pt) Benzenossulfoniluréias e -tioréias substituidas processo para sua preparação uso e medicamento
NO20002483D0 (no) Nye 19-nor-steroider substituert i posisjon 11B, fremgangsmÕte for fremstilling av slike samt mellomprodukter, deres anvendelse som medisiner, og farmasøytiske preparater inneholdende disse
BR9300250A (pt) Composto,processo para sua preparacao,medicamento e uso
BR9600773A (pt) Benzenossulfonilurélas ou - tiourélas substituídas processo para sua preparação uso e medicamento

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/525 (2006.01), A61K 38/00 (2006.0